KBC Securities - AZELIS GROUP NV (AZE) AZELIS: A formula for success, with a price to pay AZE BB

Report

KBC Securities

Thibault Leneeuw

AZELIS: A formula for success, with a price to pay AZE BB

Initiation of coverage
This note dives into the specialty chemical distribution market as we launch our coverage of Azelis. We will look at the company’s activities and how it grew to be what it is today. We’ll consider the market, the competition and the business model from which we derived our valuation. We’ll also offer additional ESG information.

25/05/2022 1 EN

Underlying

AZELIS GROUP NV

See profile

BE0974400328 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thibault Leneeuw

Other Reports on these Companies

KBC Securities

Dynamic Top Pick List Update March 2026: Removing Aedifica – Adding Proximus

The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continue into 2027. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. The highly anticipated AI productivity gains also will have to transpire sooner or later or a US market correction becomes unavoidable. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dynamic Top Pick List. The Federal Reserve (FED) will ...

March 5, 2026 March 5, 2026 1 EN

Oddo BHF

Azelis Group NV : Review of capacity additions and potential tailwinds in 2026

After a difficult year 2025, a significant rebound in chemical performance in 2026 is not very likely as weak end-market demand continues, while significant capacity additions in key feedstock like ethylene will limit the increase in utilization rates. However, some positive news, especially for European chemical producers, have come up including changes in the asphyxiating regulatory and environmental framework. Other measures, including potential anti-dumping duties and government support are also on the books and could help boost the performance of European chemical performance. That said, ...

March 3, 2026 March 3, 2026 1 FR

Oddo BHF

Azelis Group NV : Review of capacity additions and potential tailwinds in 2026

March 3, 2026 March 3, 2026 1 EN

Morning Notes : TINC BB, UCB BB, VPK NA, ZEAL DC

: TINC BB, UCB BB, VPK NA, ZEAL DC

7h / 3m 7h / 3m 1 EN

Jacob Mekhael

Jacob Mekhael

Zealand Pharma Establishes Boston research hub

Zealand announced the establishment of a new research hub in Cambridge, Massachusetts, in the greater Boston area. The facility will serve as Zealand Pharma's primary US address and is expected to be operational from September 2026. Zealand Pharma's Cambridge hub will enhance the company's research platform through AI-driven drug discovery, advanced automation, and next-generation molecule creation, accelerating the translation of scientific insight into innovative medicines. The establishment of a Boston hub was previously announced during the company's CMD in December 2025 to support its Met...

7h / 11m 7h / 11m 1 EN

Jacob Mekhael

Jacob Mekhael

UCB Picks Georgia site for planned US manufacturing facility

Yesterday after market close, UCB announced that it has selected Gwinnett County, Georgia as the location for its new US biologics manufacturing facility. Once operational, the facility is expected to produce recently approved and future pipeline complex biologics 24/7 primarily for the US market. This project is expected to generate approx. $5bn in total economic impact, creating around 330 permanent highly skilled jobs, and more than 1000 construction jobs. Approx. 62% of the company's FY25 net sales were derived from the US (vs. 54% in FY24), and we believe that number could likely go up fu...

7h / 16m 7h / 16m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

AZELIS: A formula for success, with a price to pay AZE BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Dynamic Top Pick List Update March 2026: Removing Aedifica – Adding Proximus

Azelis Group NV : Review of capacity additions and potential tailwinds in 2026

Azelis Group NV : Review of capacity additions and potential tailwinds in 2026

Morning Notes : TINC BB, UCB BB, VPK NA, ZEAL DC

Zealand Pharma Establishes Boston research hub

UCB Picks Georgia site for planned US manufacturing facility

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe